Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

BACKGROUND: Riluzole is the only approved oral drug for amyotrophic lateral sclerosis (ALS). We performed a retrospective study including ALS patients treated with riluzole, focusing on adverse events. METHODS: Patients diagnosed with ALS according to the revised El Escorial criteria (World Federati...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue-Shibui, Aya, Kato, Masaaki, Suzuki, Naoki, Kobayashi, Junpei, Takai, Yoshiki, Izumi, Rumiko, Kawauchi, Yuuko, Kuroda, Hiroshi, Warita, Hitoshi, Aoki, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487018/
https://www.ncbi.nlm.nih.gov/pubmed/31029113
http://dx.doi.org/10.1186/s12883-019-1299-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487018/
https://www.ncbi.nlm.nih.gov/pubmed/31029113
http://dx.doi.org/10.1186/s12883-019-1299-1

Ejemplares similares